Business
NetworkNewsWire Announces Publication Discussing Advances in the Manufacture of Cannabinoid Compounds for Medical Purposes
New York, New York--(Newsfile Corp. - December 7, 2017) - NetworkNewsWire ("NNW"), a multi...
About this update from Infield Minerals Corp
[{"type":"text","content":"NetworkNewsWire Announces Publication Discussing Advances in the Manufacture of Cannabinoid Compounds for Medical PurposesNew York, New York--(Newsfile Corp. - December 7, 2017) - NetworkNewsWire (\"NNW\"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.The publication, titled, \"Purified Cannabinoids Open New Opportunities in Pain Management,\" discusses advances, methodologies and innovative tools cannabis companies are using in the quest to research and develop novel products and therapies to alleviate pain.To view the full publication, visit: https://www.networknewswire.com/purified-cannabinoids-open-new-opportunities-pain-management/ \"Using its exclusive process in a controlled laboratory setting, InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) can manufacture cannabinoid compounds that are identical to those found in nature without the difficult, expensive and time-consuming challenges of planting, growing and harvesting cannabis then laboriously extracting the individual cannabinoids for medical use. It also completely eliminates any need for fertilizers or pesticides.\"Earlier this year, InMed filed a provisional U.S. patent for its pain management program (http://nnw.fm/6GHOq). The program, which includes the INM-405 therapy, along with other similar compositions of cannabinoid-based topical therapies for the treatment of pain, is an important step to not only protecting the company's commercial and intellectual property, but also in establishing themselves as a major player in the pain management industry.\" About InMedInMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed's proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value ...